A Study to Evaluate Biomarkers in Chronic Obstructive Pulmonary Disease
A Prospective Observational Study to Evaluate Biomarkers in Acute Exacerbations in Chronic Obstructive Pulmonary Disease
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Quebec
-
Sainte-Foy, Quebec, Canada, G1V 4G5
- Research Site
-
-
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Research Site
-
-
Massachusetts
-
Springfield, Massachusetts, United States, 01199
- Research Site
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Research Site
-
-
New York
-
Buffalo, New York, United States, 14215
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19140
- Research Site
-
Pittsburgh, Pennsylvania, United States, 15213
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Research Site
-
-
Texas
-
Houston, Texas, United States, 77030
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 40 years at the time of screening
- Written informed consent and any locally required authorization (eg, HIPAA in the USA, EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
- Cohort 1 only: A primary diagnosis of clinically stable physician-diagnosed COPD upon entry into the study meeting one of the following criteria:
- Subjects who have experienced a severe AECOPD requiring inpatient hospitalization in the previous 12 months
- Subject who had one severe AECOPD requiring ED visits in the past 9 months
- Subjects who are currently on LTOT.
- Cohort 1 only: Stable COPD for 4 weeks prior to screening, as defined by no change in ICS therapy and no use of oral corticosteroids or antibiotics for a respiratory tract infection.
- Cohort 1 only: Forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) < 0.70 or lower limits of normal (LLN).
- Cohort 1 only: FEV1 < 60% predicted normal value.
- Cohort 2 only: A primary diagnosis of physician-diagnosed AECOPD requiring admission to the hospital.
- Current smoker or ex-smoker with a tobacco history of ≥ 10 pack-years (one pack year = 20 cigarettes smoked per day for 1 year).
- Ability and willingness to complete the appropriate follow-up period of time as required by the protocol.
- Able to read and write and use the electronic devices (English or Spanish version).
Exclusion Criteria:
- Participation (defined as administration of at least one dose of investigational product) in another clinical study, the last follow-up visit of which is within 12 weeks (for a small molecule drug) and (6 months for a large molecule drug) of entry into this study.
- Any condition that, in the opinion of the investigator would interfere with interpretation of subject safety or study results.
- Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals.
- The presence of another chronic pulmonary or systemic disease, which in the opinion of the investigator or medical monitor might affect the analysis of the data (eg, idiopathic pulmonary fibrosis, sarcoidosis, active cancer or autoimmune disease).
- History of immunodeficiency.
- Current alcohol or drug abuse or a history of unsuccessfully treated alcohol or drug abuse within the past year.
- Cohort 2 only: Diagnosis of an acute disease/condition (eg, congestive heart failure, acute myocardial infarction, pneumonia, or pulmonary embolus) that is the primary reason for the subject's hospitalization.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Cohort 2
Subjects who are recruited on admission to hospital for AECOPD.
|
|
Cohort 1
Subjects with COPD who are stable, but at risk of presenting with an AECOPD.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Identify biomarkers for evaluation of efficacy in subjects presenting with AECOPD
Time Frame: 12 months
|
Investigate changes in physiological measures, symptoms, and blood, urine and sputum biomarkers in subjects with stable COPD during AECOPD, and as subjects return to clinical stability.
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hospitalization, treatment and discharge of COPD subjects
Time Frame: 12 months
|
Gain an understanding of the reasons subjects with COPD may be hospitalized for their AECOPD and to understand the criteria physicians use for treatment and discharge.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Joseph Parker, MD, MedImmune LLC
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MI-CP221
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.